The global immunology drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are expected to boost the market growth include the increase in the prevalence rate of the different types of cancer and rheumatoid arthritis, rising government initiatives, increasing funding from the various government and non-government organizations. The immune system is an assembly of structures and processes inside the body to protect against possibly damaging foreign bodies and diseases. It identifies various threats such as bacteria, viruses, and parasites and distinguishes them from the body's healthy tissues. When the immune system weakness and lose the capability to detect and destroy the abnormal cells or body attacks and damages its tissues lead to diseases such as cancer and autoimmune diseases.  

Immunotherapy is a process that includes the treatment by inducing, enhancing, or suppressing an immune system to fight against the diseases. According to American Autoimmune Related Diseases Association, autoimmune disease affects up to 50 million Americans. Autoimmune diseases are of 80 types out of which most prevalent are rheumatoid arthritis, Systemic Lupus Erythematous (Lupus), Juvenile rheumatoid arthritis, inflammatory bowel arthritis, Psoriatic arthritis and affects different body organs like joints, muscles, skin, red blood cells, blood vessels, connective tissues and endocrine glands.

Immunology drug is becoming a choice of several oncologists as they provide long-lasting effect by activating the immune system to identify cancerous cell and kill them through the natural process as well as improve the quality of life of cancer patients. Some of the cancer treatment vaccines approved by the US FDA include bacillus Calmette-Guérin (BCG) and Sipuleucel-T. The development of some new drugs with a success rate is expected to offer a good opportunity for the immunology drug market. The wide-ranging scope of Immuno-oncology agents in different cancer treatments would provide the maximum share to the global immunology drug market during the forecast period. Pharmaceutical companies and R&D are showing an increased interest in this field and are expected to offer a better potential for the global immunology drug market during the forecast period.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Drug Class

o By Disease Indication

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape: Johnson & Johnson Services, Inc., Novartis International AG, and AbbVie Inc., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Immunology Drug Market Report by Segment

By Drug Class

• Monoclonal Antibody (mAb)

• Immunosuppressants

• Polyclonal Antibody (pAb)

• Fusion Proteins

• Others

By Disease Indication

• Rheumatoid Arthritis

• Cancer

• Psoriatic Arthritis

• Plaque Psoriasis

• Ankylosing Spondylitis

• Inflammatory Bowel Disease

• Others

Global Immunology Drug Market by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa